Yuma Nonomiya*, Takashi Yokokawa†, Kazuyoshi Kawakami†, Kazuo Kobayashi†, Takeshi Aoyama†,
Tomomi Takiguchi†, Takahito Sugisaki†, Kenichi Suzuki†, Mitsukuni Suenaga‡, Takeru Wakatsuki‡,
Kensei Yamaguchi‡, Yoshikazu Sugimoto*, Toshihiro Hama†
Oncology Research, Vol.27, No.5, pp. 551-556, 2019, DOI:10.3727/096504018X15291727589740
Abstract Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced
hand–foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR
was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, more detailed data
regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for
regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the
hands and feet and identify preexisting risk factors for severe HFSR in Japanese patients receiving regorafenib.… More >
Login
Register
